2023 Pharma Choice DTC/DTP Bronze Winner AbelsonTaylor, Aimmune Therapeutics, and Seres Therapeutics

AbelsonTaylor, Aimmune Therapeutics, and Seres Therapeutics

C. diff Endless Sequels Journal Ad

Since recurrent C. diff is a dire condition that keeps patients coming back, the idea of endless horror-movie sequels is a perfect fit. Shining a light on the role of the microbiome in changing the ending of the same predictable plot, this campaign shapes how people think about C. diff.

AbelsonTaylor Team Members:

Brad Graetz, Group Creative Director
Lincoln Cairns, Associate Creative Director, Copy
Michael Gedraitis, Associate Creative Director, Art
Paula Lemperis, Copy Supervisor
Andrea Park, Art Supervisor

Ads

You May Also Like

PM360 2023 Trailblazer Awards Ophthalmology/Optometry Brand Champion Maaza Martin

Maaza Martin, Senior Director, Marketing, Tarsus Pharmaceuticals, Inc. Demodex blepharitis (DB) is a highly prevalent, ...

ELITE 2023 Master Educator Beth Bell of AstraZeneca

Beth Bell HCP Marketing Director – COVID-19, U.S. Respiratory & Immunology AstraZeneca Revealing the ...

Two Key Questions About Payer Strategies in 2023

PM360 asked experts in developing market access strategies about how the Inflation Reduction Act ...